Adia Nutrition Announces Successful Removal of Shell Risk Designation by OTC Markets, Advancing Toward OTCQB Uplisting
Adia Nutrition Inc. (OTC Pink: ADIA) has achieved a significant milestone by successfully removing its shell risk designation from OTC Markets, marking a important step toward uplisting from OTC Pink Sheets to the OTCQB Venture Market. This development enhances the company's market position and demonstrates its commitment to operational transparency.
The removal of the shell risk designation, a critical requirement for OTCQB status, was accomplished through close collaboration with OTC Markets. The company has been actively working to meet all uplisting criteria, including completing a comprehensive third-party audit.
CEO Larry Powalisz expressed enthusiasm about this achievement, indicating it will enable greater information sharing with investors. The OTCQB Venture Market is expected to provide enhanced transparency, liquidity, and investor trust, allowing Adia Nutrition to better showcase its stem cell therapies and nutritional products portfolio.
Adia Nutrition Inc. (OTC Pink: ADIA) ha raggiunto un traguardo significativo rimuovendo con successo la sua designazione di rischio shell dai mercati OTC, segnando un importante passo verso l'up-listing dai Pink Sheets OTC al Mercato Venture OTCQB. Questo sviluppo migliora la posizione di mercato dell'azienda e dimostra il suo impegno per la trasparenza operativa.
La rimozione della designazione di rischio shell, un requisito fondamentale per lo status OTCQB, è stata realizzata grazie a una stretta collaborazione con i mercati OTC. L'azienda ha lavorato attivamente per soddisfare tutti i criteri di up-listing, compresa la conclusione di un audit completo da parte di terzi.
Il CEO Larry Powalisz ha espresso entusiasmo per questo traguardo, indicando che permetterà una maggiore condivisione di informazioni con gli investitori. Si prevede che il Mercato Venture OTCQB offrirà maggiore trasparenza, liquidità e fiducia degli investitori, consentendo ad Adia Nutrition di mettere meglio in mostra il suo portafoglio di terapie con cellule staminali e prodotti nutrizionali.
Adia Nutrition Inc. (OTC Pink: ADIA) ha alcanzado un hito significativo al eliminar con éxito su designación de riesgo shell de los Mercados OTC, marcando un paso importante hacia la inclusión en la Mercado Venture OTCQB. Este desarrollo mejora la posición de mercado de la empresa y demuestra su compromiso con la transparencia operativa.
La eliminación de la designación de riesgo shell, un requisito crítico para el estatus OTCQB, se logró a través de una estrecha colaboración con los Mercados OTC. La empresa ha estado trabajando activamente para cumplir con todos los criterios de inclusión, incluyendo la realización de una auditoría completa por parte de terceros.
El CEO Larry Powalisz expresó entusiasmo por este logro, indicando que permitirá una mayor compartición de información con los inversores. Se espera que el Mercado Venture OTCQB proporcione mayor transparencia, liquidez y confianza de los inversores, permitiendo a Adia Nutrition mostrar mejor su cartera de terapias con células madre y productos nutricionales.
Adia Nutrition Inc. (OTC Pink: ADIA)는 OTC 시장에서 쉘 리스크 지정을 성공적으로 제거하여 중요한 이정표를 달성하였으며, 이는 OTC Pink Sheets에서 OTCQB 벤처 마켓으로의 상장 추진을 의미합니다. 이 발전은 회사의 시장 위치를 강화하고 운영 투명성에 대한 헌신을 보여줍니다.
쉘 리스크 지정을 제거하는 것은 OTCQB 상태를 위한 중요한 요건으로, OTC 시장과의 긴밀한 협력을 통해 이루어졌습니다. 회사는 모든 상장 기준을 충족하기 위해 적극적으로 노력해왔으며, 여기에는 포괄적인 제3자 감사 완료가 포함됩니다.
CEO인 Larry Powalisz는 이 성과에 대해 열정을 표하며, 이는 투자자와의 정보 공유를 더욱 원활하게 할 것이라고 밝혔습니다. OTCQB 벤처 마켓은 더 나은 투명성, 유동성 및 투자자 신뢰를 제공할 것으로 예상되며, Adia Nutrition이 줄기세포 치료제 및 영양 제품 포트폴리오를 더 잘 선보일 수 있도록 할 것입니다.
Adia Nutrition Inc. (OTC Pink: ADIA) a atteint une étape significative en supprimant avec succès sa désignation de risque shell des marchés OTC, marquant une étape importante vers l'inscription sur le Marché Venture OTCQB. Ce développement améliore la position de marché de l'entreprise et démontre son engagement envers la transparence opérationnelle.
La suppression de la désignation de risque shell, une exigence essentielle pour le statut OTCQB, a été réalisée grâce à une collaboration étroite avec les marchés OTC. L'entreprise a activement travaillé pour répondre à tous les critères d'inscription, y compris la réalisation d'un audit complet par un tiers.
Le PDG Larry Powalisz a exprimé son enthousiasme à propos de cette réalisation, indiquant que cela permettra un meilleur partage d'informations avec les investisseurs. Le Marché Venture OTCQB devrait offrir une plus grande transparence, liquidité et confiance des investisseurs, permettant à Adia Nutrition de mieux présenter son portefeuille de thérapies par cellules souches et de produits nutritionnels.
Adia Nutrition Inc. (OTC Pink: ADIA) hat einen bedeutenden Meilenstein erreicht, indem es erfolgreich die Risikobezeichnung als Shell von den OTC-Märkten entfernt hat, was einen wichtigen Schritt in Richtung Auflistung vom OTC Pink Sheets zum OTCQB Venture Market darstellt. Diese Entwicklung stärkt die Marktposition des Unternehmens und zeigt sein Engagement für betriebliche Transparenz.
Die Entfernung der Shell-Risikobezeichnung, eine wesentliche Voraussetzung für den OTCQB-Status, wurde durch enge Zusammenarbeit mit den OTC-Märkten erreicht. Das Unternehmen hat aktiv daran gearbeitet, alle Kriterien für die Auflistung zu erfüllen, einschließlich des Abschlusses eines umfassenden Audits durch Dritte.
CEO Larry Powalisz äußerte sich begeistert über diesen Erfolg und erklärte, dass dies einen besseren Informationsaustausch mit den Investoren ermöglichen werde. Der OTCQB Venture Market wird voraussichtlich mehr Transparenz, Liquidität und Vertrauen der Investoren bieten, was es Adia Nutrition ermöglicht, sein Portfolio an Stammzelltherapien und Ernährungsprodukten besser zu präsentieren.
- Successful removal of shell risk designation
- Progress toward OTCQB uplisting
- Completed third-party audit requirement
- Currently trading on less prestigious OTC Pink Sheets
Winter Park, Florida--(Newsfile Corp. - February 26, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a leader in innovative nutritional products and regenerative medical treatments, is excited to announce that it has successfully removed its shell risk designation from OTC Markets, a pivotal achievement on its accelerated journey to uplist from the OTC Pink Sheets to the OTCQB Venture Market. The company extends its heartfelt gratitude to OTC Markets for their collaboration and swift action in facilitating this milestone, reinforcing Adia Nutrition's commitment to transparency, growth, and enhanced investor visibility.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/242453_shell_risk_after_2_550.jpg
The removal of the shell risk designation was a critical requirement for achieving OTCQB status, underscoring Adia Nutrition's operational integrity and dedication to meeting elevated market standards. The company has been working closely with OTC Markets to fulfill all uplisting criteria, including a comprehensive third-party audit, and thanks OTC Markets for their partnership in expediting the shell risk removal process. This rapid progress highlights Adia Nutrition's proactive approach and sets the stage for an imminent uplisting.
"We're thrilled to have the shell risk designation lifted so quickly, and we sincerely thank OTC Markets for working with us to make this happen on our accelerated path to the OTCQB," said Larry Powalisz, CEO of Adia Nutrition. "With this hurdle cleared, I'm more confident in sharing exciting updates and information with our investors-details I wouldn't have been able to disclose before. This milestone reflects our momentum, and it's just the beginning of what's to come."
The OTCQB Venture Market offers greater transparency, liquidity, and investor trust, providing an ideal platform for Adia Nutrition to showcase its groundbreaking work in stem cell therapies and premium nutritional products to a wider audience. The swift removal of the shell risk designation demonstrates the company's efficiency and determination, promising a wealth of exciting developments on the horizon.
Stay tuned for further updates as Adia Nutrition continues to push boundaries in the industry. For more information about the company's progress or to explore its offerings, please contact at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242453
FAQ
What does the removal of shell risk designation mean for ADIA shareholders?
What requirements has ADIA completed for OTCQB uplisting in 2025?
How will ADIA's uplisting to OTCQB affect trading volume?
What products and services does ADIA focus on in 2025?
